Bispecific Antibodies: Bridging Targets and Effector Molecules
Antibody Discovery Services
Bispecific Antibodies: Bridging Targets and Effector Molecules Overview
Bispecific antibodies are a class of engineered antibodies designed to bind simultaneously to two antigens or epitopes. They serve as a crucial bridge between target cells and effector molecules or cells, enabling specific cytotoxicity of the effector cells. This mechanism plays a pivotal role in reducing the likelihood of immune escape.
Leveraging our extensive expertise in antibody development and building upon the established CLC mouse model, our company offers rapid and efficient bispecific antibody development services to our valued customers. Our one-stop service platform covers a comprehensive range of activities, including antibody sequence screening, assembly, and expression of bispecific antibodies, culminating in rigorous antibody quality control analysis.
All Antibody Discovery Services
Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.
Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.
Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.
